ASCO 2026 wasn’t just about new data—it highlighted where oncology is headed next. From breakthrough in vivo CAR-T results and RAS-targeted therapies to the growing influence of Chinese biotech on the global stage, this year’s meeting showcased the evolving future of cancer care. Listen to the recap: https://www.fiercepharma.com/pharma/behind-headlines-asco-2026
More Tips From The Bandish Group
#443: Make Sure Your References Are Up-to-Date
◆
When you’re searching for a new position, don’t wait until the last minute to contact your references. Let them know…
Obesity Drug Market: Who Can Challenge Lilly and Novo Nordisk?
◆
The global obesity drug market is rapidly becoming one of the most competitive areas in the pharmaceutical industry, with the…